2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Withdrawn
2
Completed
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1
Kidney Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Interventions
Cyclophosphamide
1499
Cisplatin
1434
Paclitaxel
1339
Radiotherapy
1310
Carboplatin
1266
Gemcitabine
1226
Docetaxel
1133
Bevacizumab
1070
Fluorouracil
906
Doxorubicin
805
Dexamethasone
755
Rituximab
744
Capecitabine
735
Oxaliplatin
709
pembrolizumab
697
Etoposide
679
Irinotecan
639
Filgrastim
624
Cytarabine
587
Nivolumab
586
Leucovorin
583
Vincristine
517
Cetuximab
479
Prednisone
478
Bortezomib
474
Trastuzumab
468
Erlotinib Hydrochloride
467
Surveys and Questionnaires
460
Methotrexate
444
Lenalidomide
436
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Molecular Imaging
×
Clear all
NCT02813226
2021-12-21
MISTER
Ontario Clinical Oncology Group (OCOG)
Phase NA
Completed
36 enrolled
NCT02228954
2021-12-07
IMPACT-RCC
Radboud University Medical Center
Completed
40 enrolled